The firm's unique business model involves financing research-stage projects to help them reach pre-clinical proof-of-concept in a semi-virtual mode. AmorChem generates returns through a two-pronged exit strategy and aims to increase the commercial potential of quality academic research carried out in Quebec. Founded in 2011, AmorChem is now on its fourth focused fund, AmorChem l.p.